Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidanceFourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior yearCompany ...
Q4 2025 earnings call: improved occupancy, FFO beat, and 2026 guidance for revenue/NOI growth, plus key risks—read now.
Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results